Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 9:38 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Completed Phase 4 Interventional

Pilot Study for Healing and Safety Outcomes in Gingival Recession

NCT04614350
View directory record Official record
Conditions
Gingival Recession
Interventions
Markman Biologics Microsurfaced ADM, AlloDerm
Biological
Lead sponsor
McGuire Institute
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 3 Interventional Results available

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

NCT05071313
View directory record Official record
Conditions
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Interventions
Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 2 Interventional

The Specific Role of Isoflavones in Reducing Prostate Cancer Risk

NCT00617617
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prevastein HC®, Placebo
Dietary Supplement · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Nov 1, 2026, 9:38 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation

NCT01669291
View directory record Official record
Conditions
Fertility
Interventions
Bravelle and Menopur, Agonist, Antagonist
Drug
Lead sponsor
Main Line Fertility Center
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718389
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
Biological · Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
119
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season

NCT02743117
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Monovalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 3 Interventional

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

NCT02932618
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Vonicog alfa, Antihemophilic Factor (Recombinant)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
16
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Completed Not applicable Interventional

A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

NCT00000943
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus Toxoid Vaccine, Hepatitis A Vaccine (Inactivated), HIV-1 Immunogen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
2
States / cities
Iowa City, Iowa • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Nov 1, 2026, 9:38 AM EST
Not listed Not applicable Interventional

The Effects of Specialty Coffee on Cognitive Function in People With Type 2 Diabetes

NCT05709847
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Coffee
Other
Lead sponsor
University of Reading
Other
Eligibility
55 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Early Phase 1 Interventional

Pilot Study of IFN α2b for Melanoma Patients

NCT00871533
View directory record Official record
Conditions
Melanoma
Interventions
IFNα2b, PEG- IFNα2b
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Nov 1, 2026, 9:38 AM EST
Not listed Phase 4 Interventional Accepts healthy volunteers

Effect of Influenza Vaccination on IVF Outcomes - IVF

NCT02947217
View directory record Official record
Conditions
Infertility
Interventions
Influenza Vaccine, Sterile Saline
Biological · Other
Lead sponsor
Center for Human Reproduction
Other
Eligibility
21 Years to 38 Years · Female only
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Nov 1, 2026, 9:38 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Up To Me: Erasing the Stigma of Mental Illness on College Campuses

NCT05784818
View directory record Official record
Conditions
Mental Illness, Behavior Disorders, Severe Mental Illness, Psychiatric Diagnosis, Psychiatric Diseases, Psychiatric Disorders, Psychiatric Illness
Interventions
Up To Me Intervention + No Booster, Up To Me Intervention + Booster
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

NCT03982199
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Tract Diseases
Interventions
RSV Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
5,815 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
40
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Not applicable Interventional Results available

Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Knee Gait Following Acquired Brain Injury

NCT00900666
View directory record Official record
Conditions
Stiff Knee Gait, Brain Injuries
Interventions
placebo, botulinum toxin A (BTX-A)
Drug
Lead sponsor
Mary Free Bed Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Phase 4 Interventional Accepts healthy volunteers

Non-surgical Alternatives to Treatment of Failed Medical Abortion

NCT02704481
View directory record Official record
Conditions
Abortion Failure
Interventions
Mifepristone, Misoprostol, Placebo mifepristone, Placebo misoprostol
Drug
Lead sponsor
Gynuity Health Projects
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
14
States / cities
Concord, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Nov 1, 2026, 9:38 AM EST
Recruiting Phase 1Phase 2 Interventional

Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients

NCT06409819
View directory record Official record
Conditions
Urinary Tract Infection, Recurrent
Interventions
phage therapy, control
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Nov 1, 2026, 9:38 AM EST
Withdrawn Phase 2 Interventional

Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome

NCT05482334
View directory record Official record
Conditions
Down Syndrome
Interventions
Sargramostim for Injection, Saline Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

NCT02690701
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Secukinumab 300 mg, Placebo
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Santa Ana, California • Rockville, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Phase 4 Interventional Results available

Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin

NCT03277183
View directory record Official record
Conditions
Anemia, CKD, Atherosclerosis, Cardiovascular
Interventions
Low dose erythropoietin, High dose erythropoietin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Nov 1, 2026, 9:38 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Role of the Gut Microbiota in Estrogen Metabolism and Dietary Flax as a Potential Modulator.

NCT03183102
View directory record Official record
Conditions
Menopause
Interventions
Flaxseed
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

NCT04611802
View directory record Official record
Conditions
SARS-CoV Infection, Covid19
Interventions
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
12 Years and older
Enrollment
33,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
144
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 3 Interventional

Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

NCT00313001
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Phase 3 Interventional Results available

Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer

NCT00360971
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
Interventions
palifermin, cisplatin, placebo, neck dissection, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Scottsdale, Arizona • Auburn, California • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 2 Interventional

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

NCT00002239
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Palm Springs, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2005 · Synced Nov 1, 2026, 9:38 AM EST